Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10434178 | 0.84 | DPP4 (0.41) | ALDH1A1KDM4EHPGDHSD17B10JAK2 | |
| SCHEMBL6632749 | 0.80 | IKBKB (0.44) | SLC9A1ALDH1A1HSD17B10RAB9A | |
| SCHEMBL6632966 | 0.78 | IKBKB (0.41) | SLC9A1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL6634881 | 0.76 | NUDT1 (0.47) | SLC9A1RAB9A | |
| SCHEMBL4238940 | 0.73 | KDM4E (0.52) | ALDH1A1KDM4EHPGDTP53GLA | |
| SCHEMBL848820 | 0.73 | — | — | |
| SCHEMBL5692656 | 0.71 | SLC9A1 (0.38) | SLC9A1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL29364307 | 0.70 | TP53 (0.61) | ALDH1A1HSD17B10TP53LMNA | |
| SCHEMBL440944 | 0.70 | TP53 (0.61) | ALDH1A1HSD17B10TP53LMNA | |
| SCHEMBL30219241 | 0.69 | ALDH1A1 (0.65) | ALDH1A1KDM4EHPGDTP53JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633369-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2020-04-28 | — | — | US | disclosed |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | 4 SC AG (DE) | 2018-07-19 | — | — | US | disclosed |
| US-9951050-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | 4SC DISCOVERY GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633369-B2 | Method of inhibiting DYRK1B | SMO, GLI1, GRK2 | SLC9A1 3943/4885ALDH1A1 3401/4885KDM4E 996/4885 |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | SLC9A1 3943/4885ALDH1A1 3401/4885KDM4E 996/4885 |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | SLC9A1 3943/4885ALDH1A1 3401/4885KDM4E 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.